NCT06499285 2026-03-11
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
Phase 3 Recruiting
Clinical Trials
69 trialsNCT05171049 2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT05171075 2025-12-19
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3 Active not recruiting
NCT06711523 2025-11-25
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
Kexing Biopharm Co., Ltd.
Phase 3 Active not recruiting
NCT04717414 2025-07-10
INDEPENDENCE
Celgene
Phase 3 Active not recruiting
NCT01130025 2025-02-24
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
LEO Pharma
Phase 3 Completed
NCT03471078 2023-09-28
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Sobi, Inc.
Phase 3 Completed
NCT05261646 2023-09-28
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Withdrawn
NCT01583218 2023-08-07
APEX
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT03036813 2023-07-27
GBT_HOPE
Pfizer
Phase 3 Completed
NCT05301517 2023-06-06
A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Kyntra Bio
Phase 3 Completed
NCT05704894 2023-01-30
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Blau Farmaceutica S.A.
Phase 3 Unknown
NCT03020160 2023-01-11
HAVEN 4
Hoffmann-La Roche
Phase 3 Completed
NCT02847637 2022-11-16
HAVEN 3
Hoffmann-La Roche
Phase 3 Completed
NCT02467868 2022-02-14
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Phase 3 Completed
NCT04466137 2022-02-09
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.
Phase 3 Completed
NCT02631070 2021-12-17
MEDALIST
Celgene
Phase 3 Completed
NCT02622321 2021-06-24
HAVEN 1
Hoffmann-La Roche
Phase 3 Completed
NCT02795767 2021-06-02
HAVEN 2
Hoffmann-La Roche
Phase 3 Completed
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT01663441 2020-09-16
A Phase â…¢a Study of Genetically Modified Recombinant Human Interleukin-11
Beijing Northland Biotech. Co., Ltd.
Phase 3 Completed
NCT01179217 2020-08-19
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Emmaus Medical, Inc.
Phase 3 Completed
NCT01928537 2020-06-30
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Traws Pharma, Inc.
Phase 3 Completed
NCT02555878 2019-09-12
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Janssen Research & Development, LLC
Phase 3 Completed
NCT01295710 2019-04-09
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Neovii Biotech
Phase 3 Completed
NCT02073682 2019-03-06
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
Phase 3 Completed
NCT03776032 2018-12-20
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
Amgen
Phase 3 Completed
NCT02389621 2018-10-30
L-PLUS 2
Shionogi Inc.
Phase 3 Completed
NCT00338286 2018-03-19
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00236951 2018-02-20
Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy
American Regent, Inc.
Phase 3 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT00711958 2017-09-05
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
Sandoz
Phase 3 Completed
NCT02767765 2017-04-04
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
Hoffmann-La Roche
Phase 3 Completed
NCT01444417 2017-02-09
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Amgen
Phase 3 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT00109538 2015-05-01
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT01101399 2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3 Completed
NCT00148421 2013-05-15
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Amgen
Phase 3 Completed
NCT00091858 2013-05-08
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Amgen
Phase 3 Completed
NCT00118638 2013-04-29
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Amgen
Phase 3 Completed
NCT00694382 2013-01-23
SAVE-ONCO
Sanofi
Phase 3 Completed
NCT01611051 2013-01-08
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT01560195 2012-11-06
A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT00210587 2011-06-10
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00210730 2011-06-10
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00341055 2011-06-10
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00261677 2011-05-23
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
Ortho Biotech Products, L.P.
Phase 3 Completed
NCT00246597 2011-05-19
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00350090 2011-05-19
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
Phase 3 Terminated